Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (273)	2/11/1999 7:58:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 804

Thanks PB. Just come home from work and read the news. OK, T revenue for full first Q (if I add initial shipment which is most appropriate than accounting it in 3Q because distribution and pts usage was in 4Q) was ~3.5 mm, or in low mid range in my prediction scale. Should I be disappointed? No, I am not. I am more than ever sure in T future. The point is MDs confidence, which will grow exponentially as words about drug efficiency spread around, from MDs to MDs. Also, there will be more, and more request from pts side, as they also become aware of the drug potential. But, T is only one part of story. There are several new development which may/will turn this company from loser to significant winner. Few points from release to support my confidence: 1. Inventory of $ 1,571,408 of T means 15.7 mm on market (90% margin, very nice isn't it!)), CELG expect significant grow in sale, 2. 8% royalty to ENMD, the some one which was in ENMD-BMY deal, 3. <<We are encouraged that this year sales are tracking above our internal forecast'', noted John W. Jackson, Chairman and CEO of Celgene.>> I do not know what was CELG forecast (~50 mm in 99, I guess), but it appears that it may be close to 70-80 mm, or even 100 mm, 4. Several presentation of the ongoing and completed T trials will bring addition fuel to fire. Enjoy, Miljenko